Targets and molecular mechanisms of triptolide in cancer therapy

作     者：Cuicui Meng Hongcheng Zhu Hongmei Song Zhongming Wang Guanhong Huang Defan Li Zhaoming Ma Jianhua Ma Qin Qin Xinchen Sun Jianxin Ma 

作者机构：Bengbu Medical College Department of Radiation OncologyThe First Affiliated Hospital of Nanjing Medical University Department of Radiation OncologyLianyungang No.2 People’s Hospital 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2014年第26卷第5期

页      面：622-626页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by a project funded by the Priority Academic Program Development of Jiangsu HigherEducation Institutions (PAPD) (JX10231801) grants from Key Academic Discipline of Jiangsu Province "Medical Aspects of Specific Environments" 

主　　题：Triptolide（TPL/TL） neoplasms antineoplastic cancer 

摘      要：Triptolide（TPL/TL） is a natural drug with novel anticancer effects. Preclinical studies indicated that TPL inhibits cell proliferation, induces cell apoptosis, inhibits tumor metastasis and enhances the effect of other therapeutic methods in various cancer cell lines. Multiple molecules and signaling pathways, such as caspases, heat-shock proteins, NF-κB, and deoxyribonucleic acid（DNA） repair-associated factors, are associated with the anti-cancer effect. TPL also improves chemoradiosensitivity in cancer therapy. Phase I trials indicate the potential clinical value of TPL use. However, further trials with larger sample sizes are needed to confirm these results.